Of the 341 men enrolled in the parent study, sufficient samples were available for 75 (22%).
RNA was extracted from patient samples that demonstrated the highest concentration of ZIKV RNA determined by the real-time assay, and for which sufficient sample volume was available (patients 824, 037, 830a, and 958).
‡Confirmatory tests were performed by 2 WB analyses and IIFT when sufficient sample was available.
Blood samples were not available from twelve individuals for one year in between years for which samples were available.
In parallel, we proceeded to profile mRNA expression in 30 of 36 liver biopsy samples, for which sufficient materials were available, including 24 HCV+ and 6 HCV- samples.
Finally, once we studied those hospitals from the MERIT study for which sufficient data were available, our findings were confirmed.
Table 12 presents the results of the subgroup analyses between studies for which sufficient data were available.
Patients with unresectable primary lesion were eligible only when sufficient biopsy samples were available for chemosensitivity testing.
Assays were repeated on samples for which sufficient plasma was available and scores for these samples were averaged.
As a measure of variability in assays of innate immune components, we repeated tests of innate immune response on several samples for which sufficient plasma was available.
